Patents Assigned to Telogene Inc.
  • Composition and methods for modulating the length of telomeres
    Publication number: 20020114797
    Abstract: The present invention relates to the length of telomeres and the role of hnRNP A1, UP1 or derivatives thereon. More particularly, the present invention relates to hnRNP A1, UP1 or derivatives thereof to maintain or alter the length of telomeres in cells. The present invention also relates to methods and compositions for increasing or decreasing the proliferative capacity of cells and to delay or precipitate the onset of senescence. The invention further relates to hnRNP A1 or UP1 or derivatives thereof as pharmaceutical, therapeutic and diagnostic reagents.
    Type: Application
    Filed: September 6, 2001
    Publication date: August 22, 2002
    Applicant: Telogene Inc.
    Inventor: Benoit Chabot
  • Methods for monitoring the binding of A1/UP1 to single-stranded nucleic acid sequences, and to measure the effect of this binding on telomere extension and protection
    Patent number: 6358687
    Abstract: The present invention relates to the length of telomeres and to their effect on proliferation and senescence in cells. More specifically, it concerns the ability of hnRNP A1 and its shortened derivative UP1 to alter the length of telomeres in cells. More precisely, the invention relates to the ability of A1/UP1 to bind telomerase RNA, to bind and to protect mammalian telomeric DNA, and to modulate telomere extension and replication. Finally, the present invention relates to agents which can interfere with the binding of A1/UP1 to telomeres and telomerase, and to the use of protection, extension and replication assays to measure the biological impact of these agents.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: March 19, 2002
    Assignee: Telogene Inc.
    Inventors: Benoit Chabot, Raymund Wellinger
  • Composition and methods for modulating the length of telomeres
    Patent number: 6294332
    Abstract: The present invention relates to the length of telomeres and the role of hnRNP A1, UP1 or derivatives thereon. More particularly, the present invention relates to hnRNP A1, UP1 or derivatives thereof to maintain or alter the length of telomeres in cells. The present invention also relates to methods and compositions for increasing or decreasing the proliferative capacity of cells and to delay or precipitate the onset of senescence The invention further relates to hnRNP A1 or UP1 or derivatives thereof as pharmaceutical, therapeutic and diagnostic reagents.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: September 25, 2001
    Assignee: Telogene Inc.
    Inventor: Benoit Chabot